Regeneron and Mammoth collaborate on gene editing therapies
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Apr 24
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
25 Apr 24
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
23 Apr 24
Ipsen would acquire an exclusive global license to develop successful development candidates (DC), by paying up to $1.8bn…
23 Apr 24
The partnership agreement, which has the potential to earn more than $1bn for Ochre Bio, aims to discover…
19 Apr 24
Collaboration Leverages Variant Bio's Cutting-edge Genomic Discovery Platform And Evotec's Integrated End-to-end R&d Platform And Disease Area Expertise…
18 Apr 24
Under the collaboration, A*STAR will offer its iPSC banks, specialised monoclonal antibody assets, process scaling, and analytics skills…
17 Apr 24
Medincell and AbbVie will co-develop up to six LAI therapeutic products whereas AbbVie will provide funding, manage the…
05 Apr 24
The German drug maker will also get an exclusive global license to develop, manufacture and market the resulting…
02 Apr 24
STRO-003, which is currently in the final stages of pre-clinical development, targets the ROR1 tumour antigen, which is…
Patient CarePharmaceuticals and MedicinesPartnerships and Licensing Agreements
29 Mar 24
XTX301, which is a tumour-activated IL-12 designed to accelerate anti-tumour immunity, is currently being evaluated for its safety…